These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19100711)

  • 1. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1.
    Matyas GR; Beck Z; Karasavvas N; Alving CR
    Biochim Biophys Acta; 2009 Mar; 1788(3):660-5. PubMed ID: 19100711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
    J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
    Matyas GR; Wieczorek L; Beck Z; Ochsenbauer-Jambor C; Kappes JC; Michael NL; Polonis VR; Alving CR
    AIDS; 2009 Oct; 23(16):2069-77. PubMed ID: 19710597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
    Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
    J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.
    Sánchez-Martínez S; Lorizate M; Katinger H; Kunert R; Nieva JL
    AIDS Res Hum Retroviruses; 2006 Oct; 22(10):998-1006. PubMed ID: 17067270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
    Franquelim HG; Chiantia S; Veiga AS; Santos NC; Schwille P; Castanho MA
    AIDS; 2011 Feb; 25(4):419-28. PubMed ID: 21245727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.
    Scherer EM; Zwick MB; Teyton L; Burton DR
    AIDS; 2007 Oct; 21(16):2131-9. PubMed ID: 18090039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
    Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
    Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
    Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
    AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope.
    Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J
    AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
    Huarte N; Lorizate M; Kunert R; Nieva JL
    FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
    Menendez A; Chow KC; Pan OC; Scott JK
    J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
    Shen X; Dennison SM; Liu P; Gao F; Jaeger F; Montefiori DC; Verkoczy L; Haynes BF; Alam SM; Tomaras GD
    Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5972-7. PubMed ID: 20231447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide.
    Morris GC; Wiggins RC; Woodhall SC; Bland JM; Taylor CR; Jespers V; Vcelar BA; Lacey CJ
    PLoS One; 2014; 9(12):e116153. PubMed ID: 25546420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization.
    Peachman KK; Wieczorek L; Matyas GR; Polonis VR; Alving CR; Rao M
    Viral Immunol; 2010 Dec; 23(6):627-32. PubMed ID: 21142448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.